Skip to content

Study · Animal study (in vivo) · outbred white mice · 2003

5 results

[The antiviral activity of the peptide immunomodulator "Gepon" in experimental models of street rabies virus].

Gribencha SV, Kholms RD, Ataullakhanov RI, Barinskiĭ IF

Voprosy virusologii1 Jul 2003

PMID12945207 (opens in a new tab)PepBankPUB-12945207
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In outbred white mice, intracerebral Gepon at 0.01-0.1 micrograms was non-toxic.

    In plain wordsIn mice, Gepon injected into the brain at 0.01-0.1 micrograms was non-toxic.

    Peptide
    Gepon
    Outcome
    Direction not reportedToxicity
    Study

    outbred white micen: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.01-0.1 micrograms · intracerebralAs given in this study (outbred white mice).

    Source sentences

    Summary
    Intracerebral injections of the Gepon drug were shown to be non-toxic when administered to outbred white mice, 0.01-0.1 micrograms.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice infected with street rabies virus, Gepon protected 30-40% of animals.

    In plain wordsIn mice infected with street rabies virus, Gepon protected 30-40% of animals.

    Peptide
    Gepon
    Outcome
    IncreaseProtection against street rabies virus
    Study

    outbred white micen: not reported in source

    Street rabies virus infection
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The drug protects 30-40% of mice (p < 95-99%) in contamination by street rables virus.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice infected with street rabies virus, protection with Gepon depended on dose and administration scheme.

    In plain wordsIn mice infected with street rabies virus, Gepon protection depended on dose and administration scheme.

    Peptide
    Gepon
    Outcome
    Direction not reportedDose and administration scheme dependence of protection
    Study

    outbred white micen: not reported in source

    Street rabies virus infection
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The animals' protection depends on a dose and drug application scheme.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice infected with street rabies virus, intramuscular Gepon at 0.1 microgram in the virus locus produced the most pronounced protection.

    In plain wordsIn mice, Gepon at 0.1 microgram injected into muscle at the virus entry site produced the greatest protection.

    Peptide
    Gepon
    Outcome
    IncreaseProtection with intramuscular administration
    Study

    outbred white micen: not reported in source

    Street rabies virus infection
    Outcome group
    Antiviral activity · Infection
    Studied dose
    0.1 microgram · intramuscular in the virus locusAs given in this study (outbred white mice).

    Source sentences

    Summary
    The most pronounced protection was observed in its intramuscular administration, 0.1 microgram in the virus locus (infection opening).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice, therapeutic Gepon administration after viral infection produced 40% protection (p < 0.01).

    In plain wordsIn mice, Gepon given after viral infection produced 40% protection.

    Peptide
    Gepon
    Outcome
    IncreaseProtection after infection
    Study

    outbred white micen: not reported in source

    Street rabies virus infection
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It should be necessarily pointed out that such pronounced protection (40%; p < 0.01) was noted within the therapeutic scheme of drug administration after virus infected the animals.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.